8 results
Oral anticoagulant dosing and bridging for VTE

- Dr. Joseph Shatzel @Clotmaster 

#VTE #DOAC #Bridging #Dosing #Oral
Oral anticoagulant ... #DOAC #Bridging ... #Dosing #Oral #Anticoagulant ... #Anticoagulation ... #Dabigatran #Apixaban
Heparin, Fondaparinux, and Novel Oral Anticoagulants - Pathophysiology

Anticoagulation with parenteral (intravenous or subcutaneous) and oral anticoagulants
and Novel Oral Anticoagulants ... or a new oral anticoagulant ... traditional oral anticoagulant ... #UFH #DOAC #Dabigatran ... #Fondaparinux #NOAC
Anticoagulants Common Reversal Agents
 - Warfarin (Coumadin) → Vitamin K (Phytonadione), 4-factor PCC (Kcentra)
 - Heparin/LMWH
Anticoagulants Common ... PCC (Kcentra) - Heparin ... (Praxbind) - Apixaban ... #doac #noac #pharmacology ... #hematology #reversal
Patient risk stratification algorithm for the treatment of cancer-associated thrombosis.

Currently, edoxaban and rivaroxaban are the only
direct-acting oral anticoagulants ... filtration rate; DOAC ... direct-acting oral anticoagulant ... molecular weight heparin ... #DOAC #VTE #Malignancy
Treatment algorithm for VTE in Malignancy

(A) Suggested treatment algorithm for symptomatic and incidental DVT or PE
consider withholding anticoagulant ... DOAC, direct oral ... anticoagulant; ... low-molecular-weight heparin ... #DOAC #VTE #Malignancy
Effect of Direct Oral Anticoagulants on Hemostatic Tests
Horizontal bars correspond to the approximate range of detectability
of Direct Oral Anticoagulants ... , rixaroxaban, apixaban ... and edoxaban. ... thrombin time #doac ... #noac #anticoagulation
The coagulation cascade is shown, separated into different phases with their endogenous and pharmacological inhibitors shown.
#models #hematology ... #pathophysiology ... #anticoagulation ... #anticoagulant ... #heparin #pathway
Causes of Abnormal PT and/or aPTT
Prolonged Prothrombin Time (PT)
1. Acquired deficiency of FVII
, edoxaban (typically ... unfractionated heparin ... - Other anticoagulants ... cause e.g. heparin ... thrombin inhibitors, heparin